Cambridge, UK 2/27/14—Horizon Discovery plans to raise £25 million ($42 million = £0.60 = $1) through an IPO on the London Stock Exchange’s AIM market. Horizon supplies the GENESIS gene editing and X MAN cell line platforms for genomics research and the development of personalized medicines. In 2013, Horizon revenues grew more than 70% to £6.6 million ($10.3 million = £0.64 = $1), and the company had a total of 353 unique customers. The company has three commercial units: contract research services, cell line and reagent products, and leverage R&D. “Horizon Discovery is at a very exciting stage in its development where investments made into the scale up of its three commercial units will accelerate growth, transforming the Company into a global market leader in translational genomics research tools,” stated Horizon CEO Darrin Disley. “An IPO further enhances the profile of Horizon Discovery, facilitating the expansion of our sales and distribution channels, expansion of our product lines and increasing opportunities to engage in leveraged R&D. It also allows us to acquire additional IP and commercial offerings, including sales channels that will enhance our geographic reach.”